7/30/2014 6:11:10 AM
(Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.
Shares of Impax, which makes generics and specialty drugs to treat central nervous system disorders, fell as much as 17 percent on Tuesday, after the regulator listed 10 violations at the plant.
Unsatisfactory manufacturing practices have become an Achilles' heel for Impax.
Help employers find you! Check out all the jobs and post your resume.
comments powered by